top of page

DEPRESSION

What is Depression?

Is it a mental illness or a disease of the brain?

Recent studies have shown that depression is a disease of the brain, not a disease of the mind. The incidence of depression is twice as high in women as in men.


In people with depression, there are changes in the electrical, chemical, hormonal, and magnetic fields of the brain. Depression arises as a result of this imbalance. It can occur genetically or due to environmental factors.

These changes lead to what we call psychological symptoms.

e499dd_f1f1d908476a425fbe6a5500915fd5e7~mv2.avif

What Do People with Depression Feel?

Lack of enjoyment in life

Lack of enjoyment in hobbies

Desire to die or suicidal thoughts, and even suicide plans

Decreased energy

Decreased sexual energy

Attention and concentration problems

Memory problems

Decreased or increased appetite

Weight loss or gain (more than 5% of normal weight)

Sleep problems (difficulty falling asleep, waking up repeatedly during sleep, most strikingly waking up around 3-4 am, reluctance to get up in the morning, reluctance to get out of bed)

Decreased socialization

They may become unable to follow TV or newspapers

Daily functions and self-care decrease

Negative outlook on life and oneself, and feelings of guilt may be observed.

Many people may say they are depressed, but to be diagnosed with clinical depression, all or some of these symptoms must last for at least two weeks.

274594_25b25baa73dd46c7910c036b6cae4183~mv2_d_5472_3648_s_4_2.avif

Depression and Suicide:

During my years working at Columbia University as the chief assistant to world-renowned doctors Ronald Fieve and Donald Dunner, who specialize in the diagnosis and treatment of depression and bipolar disorder;

They would tell me about female patients who would come to the doctor's office, regularly applying makeup, saying they were depressed, and then commit suicide a week later; and they would carefully emphasize that such cases could mislead doctors.


​5% of Depressed Patients Commit Suicide!

​Two-thirds of depressed patients may have suicidal thoughts.

They may have impulsive thoughts of harming another person.

Medications can increase the risk of suicide:


Antiepileptic drugs increase the risk of suicide (FDA Alert: "Suicidality and Antiepileptic Drugs," Jan. 31, 2008.) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116847.htm

Medscape Health News 2008, Yael Waknine mentioned that the FDA (American Food and Drug Administration) stated that antiepileptics increase the risk of suicide.


Psychotic Depression:

In the psychotic type of depression, the patient shows detachment from real life. Hallucinations and thought disorders may occur.
Seasonal Depression:
The type called seasonal depression occurs every year during the period when the sun is less intense.

Anxiety and Depression:

Some people with depression may also develop Anxiety Disorder as a secondary illness, characterized by excessive worry and somatic complaints.


Drug and Alcohol Use:
Secondary depression can occur due to drug and alcohol use; some of these individuals were already depressed before substance use. If depression occurs with substance use, we call this dual depression.

Head Trauma-Related Depression:
Some people may develop secondary depression due to head trauma in childhood or adulthood, with or without loss of consciousness, and these individuals generally do not respond well or at all to medication.

Depression in Other Diseases:

40-60% of Parkinson's patients

50% of stroke (due to brain paralysis, hemorrhage, or blood clot) patients

40% of Alzheimer's patients

30% of trauma patients

30% of Multiple Sclerosis patients experience depression.

Postpartum,

Epilepsy (Seizure Disorder),

AIDS,

Thyroid disease,

Systemic Lupus Disease,

Depression can also develop due to vitamin deficiencies such as B12, B6, D, C, and folic acid.

 


Depression can develop due to some medications:

Some high blood pressure medications (such as beta-blockers and reserpine)

Some heart medications (such as digitalis and veratrum)

Cortisone and hormones (birth control pills)

Amphetamine-group medications (Ritalin)

Analgesics (Ibuprofen and morphine derivatives)


How is Depression Diagnosed?

The patient's history is very important in diagnosis.

It is important to know whether the patient's family members have a history of the illness, and if so, whether they used medication and, if so, which medication they used. Misdiagnosis often occurs during the patient's history taking.

If the patient comes to you with their family, you can also learn about the symptoms from them; the family may provide answers that the patient does not.

QEEG Database-Based Depression Diagnosis Method:
Our center has been using several QEEG database systems approved by the FDA (Food and Drug Administration) in the USA since 2000, pioneering this method in Turkey.

The brain's electrical activity is recorded with Digital EEG, and the patient's brainwaves are compared with those of patients with Depression and Manic Depression using the NxLink Data Bank, developed by New York University through 20 years of research. This system can also determine whether these individuals have experienced a head trauma.

 

This system, with 90-94% accuracy, objectively assists in our clinical diagnosis, helping to differentiate whether a patient's symptoms are due to depression, manic depression, or head trauma.[1] Of course, diagnosis must be made based on clinical findings, digital EEG and database analysis, and the clinician's decision.

Hypomania:

Furthermore, some hypomanic patients present to their doctors for the first time with symptoms of depression, and hypomanic episodes occur or are triggered when antidepressants are prescribed. With the QEEG database, these potential patients can be easily identified objectively before treatment even begins.


We Must Reduce Misdiagnosis:

Many cases of depression who have not responded to treatment for years have come to our center as a last resort. Some of these patients do not want to use medication.

A significant number of these patients learned, after undergoing digital EEG and database review, that they did not have

Depression, but rather

Manic Depression or

Secondary depression due to a previous head injury.

Some patients experienced symptoms of depression or manic depression-like symptoms some time after receiving a head injury.

It appears as a secondary cause.

A QEEG-Data Bank analysis can determine if the patient has experienced a head trauma.

Often, electrical changes in the brain that do not show up on a classic EEG are linked to head trauma on QEEG recordings, and this is why the patient does not respond to medication.

Thus, we determine whether the patient's depression or manic depression is due to a primary cause or a secondary cause arising from head trauma.

Treatment of Depression:
Treatment of depression generally involves medication, psychotherapy, cognitive therapy, family therapy, hypnosis, and electroshock therapy.

Treatment of Depression in Children May Be Drug-Free:

The world's leading organizations (such as NICE) recommend against the use of psychiatric medications as a first-line treatment for children.

Drug Meta-Analysis Treatment:
Meta-analysis studies of proven drug treatments in psychiatry have shown that they are not statistically different from placebo in mild and moderate depression.[2],[3]

In the publication “New Directions in Psychiatry” in Psychiatric Times, the ineffectiveness of psychiatric drugs was revisited.[4]
Electroshock Therapy (ECT):
ECT (Electroshock), which has a statistically significant risk of causing death among its serious side effects,[5] is widely accepted in psychiatry. However, while placebo-controlled studies of Electroconvulsive Therapy (ECT) have shown a small degree of effectiveness for Depression and Schizophrenia, there are no placebo-controlled studies showing that it reduces the risk of suicide.

Promising Treatments for Depression:

Since the above treatments are not effective for many patients, promising treatments have recently been developed, including:

Neurofeedback Therapy

Magnetotherapy

MRI Therapy

...and more.

Neurofeedback Treatment for Depression:

For our patients who want drug-free treatment, we are achieving successful results with the Neurofeedback brain training system. We see that this method can permanently eliminate the problem with a treatment period of 2-3 months, and the best part is that it has no side effects and allows you to live a drug-free life.

Let's not forget that no treatment method in the world is 100% successful. Neurofeedback is around 80% successful and generally permanent.

If you have sleep problems, 5-10 sessions of sleep therapy can help you sleep soundly and wake up feeling refreshed in the morning.

Working on the area related to happiness can help you enjoy life, working on the attention center can help you focus your attention easily, and working on the memory area can help improve memory problems.

Neurofeedback Therapy Can Be Effective Even in Scientifically and Drug-Resistant Cases:

In a randomized controlled trial of neurofeedback (NF), psychotherapy, and placebo in patients with depression, improvement was observed in the NF group, while no improvement was seen in the placebo and psychotherapy groups.[6]

 

A controlled neurofeedback f-MRI study with 31 people examined whether mood changed after a single session.[7]

 

Another study investigated the effects of psychoneurotherapy on abnormal EEG activity in individuals with major depressive disorder. Electromagnetic abnormalities detected in individuals with major depressive disorder were identified according to brain electromagnetic tomography (LORETA) and normative EEG database. Detections were made before and after treatment using LORETA. High beta (18-30Hz) detected in the frontotemporal areas before treatment was found to normalize after treatment, and clinical improvement was also observed in the subjects. It was concluded that normalizing high beta activity was associated with a significant reduction in depressive symptoms.[8]

 

In a controlled study using fMRI neurofeedback, neurofeedback was found to be effective in the treatment of depression.[9]

 

Walker, with a new protocol, was able to create more than 50% improvement in 84% of 183 drug-resistant depression patients with 6 sessions of neurofeedback.[10] He also found that it was permanent in 99% of patients after 1 year of follow-up.

 

Zotev et al., in their 2013 fMRI neurofeedback study, determined that the right anterior cingulate cortex plays a role in emotion control in 24 normal individuals (12 real individuals received neurofeedback, 12 individuals received sham neurofeedback). They thought it could be important in the treatment of patients with mood disorders such as depression.[11]

In a study of 21 patients with unmedicated depression, 14 received fMRI NF, while 7 depression patients in the control group received sham fMRI NF. Only the group receiving real fMRI NF, which regulates the amygdala, showed improvement in their depression.[12]

 

In a comparison of 40 depression patients with a normal group, neurofeedback showed that working memory problems, a major symptom of depression, improved only in the neurofeedback group.[13]

 

Neurofeedback was found to be effective in the treatment of depression and its effects were sustained over a 5-year follow-up.[14]

Biofeedback Therapy Added to Depression Treatment Guidelines:

The Anxiety and Depression Association of America and the National Institutes of Health, National Center for Complementary and Alternative Medicine have added biofeedback therapy to the treatment guidelines for anxiety disorders and stress.[15]

The American Academy of Sleep Medicine recommends biofeedback as an effective method within the evidence-based medicine criteria for the treatment of chronic insomnia and has added it to its treatment guidelines.[16]

It is stated in many scientific publications that hypnotic drugs used in sleep disorders cause depression[17] and can cause death as deadly as smoking and cause some types of cancer.[18]-[19]-[20]-[21]-[22]

[1] Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 9th Edition. Sadock BJ, Sadock V. A, Ruiz P. Jun 8, 2009

[2] Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment, Volume 1, Article 0002a, posted June 26, 1998Copyright 1998 by the American Psychological Associationhttp://psychrights.org/research/Digest/CriticalThinkRxCites/KirschandSapirstein1998.pdf

[3] Pigott, H.E., Leventhal, A.M., Alter, G.S., Boren,J.J.( 2010). Efficacy and Effectiveness of

Antidepressants: Current Status of Research. Psychother Psychosom. February 22;79:267–279

[4] http://www.psychiatrictimes.com/cultural-psychiatry/new-directions-psychiatry

[5] Read J.,Bentali R.( 2010) The effectiveness of Electroconvulsive therapy: A literature review.Epidemiologia Psychiatria Sociale. 333-347

[6] Choi S.W., Chi S.E., Chung S.Y., Kim J.W., Ahn C.Y., Kim H.T. Is Alpha Wave Neurofeedback Effective with Randomized Clinical Trials in Depression? A Pilot Study.Neuropsychobiology 2011;63:43–51

[7] Johnston S., Linden D. E. J., Healy D., Goebel R., Habes I., Boehm S. G. Upregulation of emotion areas through neurofeedback with a focus on positive mood. Cogn Affect Behav Neurosci2011 Mar;11(1):44-51

[8] Paquette, V., Beauregard, M., Prévost, D.B.(2009). Effect of a psychoneurotherapy on brain electromagnetic tomography in individuals with major depressive disorder. Psychiatry Research: Neuroimaging. doi : 10.1016/j.pscychresns.2009.06.002

[9] Linden DE, Habes I, Johnston SJ, Linden S, Tatineni R, Subramanian L, Sorger B, Healy D, Goebel R.

Real-time self-regulation of emotion networks in patients with depression.PLoS One. 2012;7(6):e38115. doi: 10.1371/journal.pone.0038115. Epub 2012 Jun 4.

[10] Walker JE, Lawson R. (2013). FP02 Beta Training for Drug-Resistant Depression-A New Protocol That Usually Reduces Depression and Keeps It Reduced. Journal of Neurotherapy, 17:198–200

[11] Zotev V, Phillips R, Young KD, Drevets WC, Bodurka.(2013). Prefrontal control of the amygdala during real-time fMRI neurofeedback training of emotion regulation.J.PLoS One. 2013 Nov 6;8(11):e79184. doi: 10.1371/journal.pone.0079184. eCollection.

[12] Young KD, Zotev V, Phillips R, Misaki M, Yuan H, Drevets WC, Bodurka J.(2014). Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder.PLoS One. 2014 Feb 11;9 (2):e88785. doi: 10.1371/journal.pone.0088785. eCollection.

[13] Escolano C, Navarro-Gil M, Garcia-Campayo J, Congedo M, De Ridder D, Minguez J.A controlled study on the cognitive effect of alpha neurofeedback training in patients with major depressive disorder.Front Behav Neurosci.2014 Sep 2;8:296.

[14] Baher E, Rosenfeld JP, Baehr R. The clinical use of an alpha symmetry protocol in the neurofeedback treatment of depression: follow-up study one to five years post therapy. J Neurotherapy 2001;4(4):11-18

[15] http://nccam.nih.gov/health/stress/relaxation.htm

[16] http://www.aasmnet.org/resources/flipping/Membernewsletter/Issue3/files/assets/basic-html/page8.html

[17] Kripke DF.Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007 Aug 21;7:42.

[18]Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res. 2008 Sep;17(3):245-50. doi: 10.1111/j.1365-2869.2008.00685.x.

[19] Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study.

BMJOpen. 2012 Feb 27;2(1):e000850. doi: 10.1136/bmjopen-2012-000850. Print 2012.

[20] Merlo J, Hedblad B, Ogren M, et al. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Eur J Clin Pharmacol 1996;49:261e5.

[21] Kripke DF, Klauber MR, Wingard DL, et al. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998;43:687e93.

[22] Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med 2009;10:279e86.

Neurofeedback Treatment for Depression:

Psychiatrist Prof. Dr. Thomas Insel, President of the National Institutes of Health (NIMH), stated in an article dated April 29, 2013, on the NIMH website, that "the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has little validity, and patients with mental health disorders deserve better. For years, we have rejected biological markers because they were not identified in DSM categories," whereas biological markers are important.

Prof. In another article examining the current state of drug treatment, Professor İnsel notes that psychiatric medications are widely used in mental health treatment for both children and adults. He points out that while comparative studies funded by NIMH show that new types of psychiatric drugs have not been superior to older types, their use has dramatically increased in the last 10-20 years. However, despite the fact that psychiatric drugs had a sales potential of $25 billion in 2007, this increase has not been effective in preventing psychiatric illnesses or reducing deaths from these illnesses.

Professor İnsel states, “The psychiatric medications we currently use help very few people get better, or very few people actually recover. While many studies are expected and even desired to measure the long-term effects of these drugs, research has focused on their short-term effects. Just as it is clear that we made a mistake 30 years ago, we may still be saying ‘We made a mistake’ 30 years from now.”

 

Dr. Christian Fibiger, former Vice President of Eli Lily, one of the leading pharmaceutical companies, stated that "psychopharmacology is in crisis, the data clearly shows that widespread drug trials have failed, and that decades of research and billions of dollars spent on psychiatric drugs have not resulted in a single unparalleled effective drug in 30 years." This shows that Dr. Insel is not alone in this regard.

Prof. Dr. Insel emphasizes the necessity of using biological markers (for example, QEEG is a biological marker) in diagnosis. He explains that the limitations of drugs are evident from scientific data.

The NIHMH Research Domain Criteria (RDoC) project, starting in 2008, indicates that funding for all psychiatric research will be possible with the inclusion of biological markers in studies. QEEG and Neurobiofeedback contribute to these biological markers.

In psychiatric medicine, meta-analysis studies of proven drug treatments have shown that they are not statistically different from placebo in mild to moderate depression.

The publication “New Directions in Psychiatry” in Psychiatric Times revisited the ineffectiveness of psychiatric medications.

[1] http://www.nimh.nih.gov/about/director/2013/transforming-diagnosis.shtml

[2] Insel, T. R. (2009). Disruptive insights in psychiatry: Transforming a clinical discipline. Journal of

Clinical Investigation, 119(4), 700–705

[3] Fibiger HC (2012). Psychiatry, the pharmaceutical industry, and the road to better therapeutics.

Schizophrenia Bulletin, 38(4), 649–650

[4] https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml

[5] Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of

an*depressant medica*on. Preven*on and Treatment, Volume 1, Ar*cle 0002a, posted June 26,

1998Copyright 1998 by the American Psychological Associa*on

h3p://psychrights.org/research/Digest/Cri*calThinkRxCites/KirschandSapirstein1998.pdf

[6] Pigo3, H.E., Leventhal, A.M., Alter, G.S., Boren,J.J.( 2010). E=cacy and E>ec*veness of An*depressants: Current

Status of Research. Psychother Psychosom. February 22;79:267–279

[7] h3p://www.psychiatric*mes.com/cultural-psychiatry/new-direc*ons-psychiatry

Breakthrough in Depression Treatment

274594_25b25baa73dd46c7910c036b6cae4183~mv2_d_5472_3648_s_4_2.avif

A technique known as fMRI neurofeedback has revolutionized the treatment of depression. The technique, which stimulates a part of the brain known to be involved in depression, by recalling positive memories, offers a chance to overcome the disorder.

A new study suggests that a non-invasive technique that stimulates a part of the brain known to be involved in depression could offer significant benefits for people with the disorder. The technique involves observing a person's amygdala activity and consciously trying to increase that activity by recalling positive memories. This is called fMRI neurofeedback.

Kymberly Young, the lead author of the new study and a psychiatry assistant at the University of Pittsburgh School of Medicine, said that although the experiment was small, it yielded promising results.

For this study, Young divided 36 adult volunteers with depression into two groups. One group received neurofeedback on their amygdala, and the other was a control group that underwent a sham neurofeedback exercise that did not involve the brain's emotional processing. People in both groups had their brains scanned with fMRI to identify the amygdala, or control center of the brain.

Then, researchers showed participants a signal from the measured part of the brain, and the participants tried to regulate the strength of this signal by recalling happy moments.

http://www.habertuneli.com/fmri-neurofeedback/depresyon-tedavisinde-cigir-acildi

bottom of page